Cencora, Inc. (COR)
NYSE · Conshohocken, Pennsylvania, USA · Founded 2001 · CEO Robert Mauch
Valuation summary
$389.59 fair value versus $341.25 in the market, a difference of +14.2%. Rated Buy.
| Fair value per share | $389.59 |
| Current share price | $341.25 |
| Upside / downside | +14.2% |
| Bear case | N/M |
| Bull case | $1,453.48 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.50% |
| Market capitalisation | $65B |
| EV / Sales | 0.2x |
About Cencora, Inc.
Formed in 2001 by the merger of AmerisourceBergen's two predecessors and renamed Cencora in 2023. Robert Mauch has been chief executive since October 2024. Cencora is one of the three wholesalers that distribute most prescription drugs in the United States, buying from drug makers and delivering to pharmacies, hospitals and clinics. It is especially strong in specialty drugs for cancer and other complex conditions, and also runs World Courier and global services for drug makers.
Investment case
- Part of a three-company oligopoly in US drug distribution.
- Specialty drugs and GLP-1 weight-loss drugs lift volumes.
- Steady cash flow and share buybacks.
Key risks
- Margins are wafer-thin, so small changes in pricing matter a lot.
- Walgreens is a very large customer.
- Drug pricing reform could change how distributors are paid.
Revenue by segment
| US Healthcare Solutions | 90% |
| International Healthcare Solutions | 10% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $352.5B | $3.0B |
| Year 2 | $370.2B | $3.4B |
| Year 3 | $388.7B | $4.0B |
| Year 4 | $408.1B | $4.5B |
| Year 5 | $428.5B | $5.1B |
What the street says
A low-risk compounder in healthcare distribution, with specialty drugs the growth driver.
Comparable companies: CAH · ELV · MCK · CI · UNH · MDLN · CVS · GEHC
Open the interactive model, price chart and sensitivity grid →